Lenalidomide
CAS 191732-72-6 20 FDA-DMF suppliersSmall Molecule
Overview
Lenalidomide is a derivative of thalidomide with immunomodulatory and antiangiogenic properties. It is used in the treatment of various types of cancer, particularly multiple myeloma, and certain hematological disorders.
API suppliers (3)
Suppliers of Lenalidomide backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.
- Cipla USA, Inc.USA2 active DMF
- MATRIX PHARMACORP PRIVATE LTD1 active DMF
- MYLAN LABORATORIES LTD
Patent & exclusivity (US)
Per the FDA Orange Book (113 approved US products), the latest listed US patent on Lenalidomide expires 8 Mar 2028 and exclusivity 27 May 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyHematologyImmunology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.